DelveInsight’s report titled “Neuroendocrine Tumors Pipeline Insight 2023” offers extensive information on more than 55+ companies and over 60+ pipeline drugs in the field of Neuroendocrine Tumors research. The Neuroendocrine Tumors pipeline report encompasses detailed profiles of the pipeline drugs for Neuroendocrine Tumors, including information on Neuroendocrine Tumors clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Neuroendocrine Tumors emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Neuroendocrine Tumors pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Neuroendocrine Tumors clinical trial studies conducted for Neuroendocrine Tumors, any NDA approvals obtained for Neuroendocrine Tumors, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Neuroendocrine Tumors Pipeline treatment landscape of the report, click here @ Neuroendocrine Tumors Pipeline Outlook
Key Takeaways from the Neuroendocrine Tumors Pipeline Report
DelveInsight’s Neuroendocrine Tumors Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline treatment therapies.
The leading Neuroendocrine Tumors Companies are working in the market include Jiangsu Hengrui, Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others
Emerging Neuroendocrine Tumors Pipeline Therapies in the various stages of development include AlphaMedix, 177Lu-DOTA-EB-TATE, Amino Acid Solution, octreotide FluidCrystal® injection depot, Everolimus, Pelcitoclax, 64Cu-SARTATE, and others
On July, 2022, Molecular Targeting Technologies Inc announced a drug with the name of 177Lu-DOTA-EB-TATE by the phase 1. This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
On January, 2022, Radiomedix Inc announced a drug with name of AlphaMedix by the phase 1. Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive).
Neuroendocrine Tumors Overview
A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body.
For further information, refer to the detailed Neuroendocrine Tumors Unmet Needs, Neuroendocrine Tumors Market Drivers, and Market Barriers, click here for Neuroendocrine Tumors Ongoing Clinical Trial Analysis
Neuroendocrine Tumors Emerging Drugs Profile
ITM-11: ITM Solucin
Alphamedix: RadioMedix
BI 764532: Boehringer Ingelheim
Neuroendocrine Tumors Pipeline Therapeutics Assessment
There are approx. 55+ Neuroendocrine Tumors companies which are developing the therapies for Neuroendocrine Tumors. The Neuroendocrine Tumors companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. phase III include, ITM Solucin.
Request a sample and discover the recent advances in Neuroendocrine Tumors Ongoing Clinical Trial Analysis and Medications, click here @ Neuroendocrine Tumors Treatment Landscape
Neuroendocrine Tumors Therapeutics Assessment
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Some of the Companies in the Neuroendocrine Tumors Therapeutics Market include-
Jiangsu Hengrui, Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
Dive deep into rich insights for drugs for Neuroendocrine Tumors Pipeline, click here @ Neuroendocrine Tumors Unmet Needs and Analyst Views
Scope of the Neuroendocrine Tumors Pipeline Report
Coverage- Global
Neuroendocrine Tumors Companies– Jiangsu Hengrui, Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
Neuroendocrine Tumors Therapies- AlphaMedix, 177Lu-DOTA-EB-TATE, Amino Acid Solution, octreotide FluidCrystal® injection depot, Everolimus, Pelcitoclax, 64Cu-SARTATE, and others
Neuroendocrine Tumors Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Neuroendocrine Tumors Mergers and acquisitions, Neuroendocrine Tumors Licensing Activities @ Neuroendocrine Tumors Emerging Drugs, and Recent Trends
Table of Content
Introduction
Neuroendocrine Tumors Executive Summary
Neuroendocrine Tumors: Overview
Neuroendocrine Tumors Pipeline Therapeutics
Neuroendocrine Tumors Therapeutic Assessment
Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ITM-11: ITM Solucin
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Alphamedix: RadioMedix
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BI 764532: Boehringer Ingelheim
Drug profiles in the detailed report…..
Inactive Products
Neuroendocrine Tumors Key Companies
Neuroendocrine Tumors Key Products
Neuroendocrine Tumors – Unmet Needs
Neuroendocrine Tumors – Market Drivers and Barriers
Neuroendocrine Tumors – Future Perspectives and Conclusion
Neuroendocrine Tumors Analyst Views
Neuroendocrine Tumors Key Companies
Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage